A breast cancer gene signature for indolent disease

PurposeEarly-stage hormone-receptor positive breast cancer is treated with endocrine therapy and the recommended duration of these treatments has increased over time. While endocrine therapy is considered less of a burden to patients compared to chemotherapy, long-term adherence may be low due to potential adverse side effects as well as compliance fatigue. It is of high clinical utility to identify subgroups of breast cancer patients who may have excellent long-term survival without or with limited duration of endocrine therapy to aid in personalizing endocrine treatment.MethodsWe describe a new ultralow risk threshold for the 70-gene signature (MammaPrint) that identifies a group of breast cancer patients with excellent 20 year, long-term survival prognosis. Tumors of these patients are referred to as “indolent breast cancer.” We used patient series on which we previously established and assessed the 70-gene signature high–low risk threshold.ResultsIn an independent validation cohort, we show that patients with indolent breast cancer had 100% breast cancer-specific survival at 15 years of follow-up.ConclusionsOur data indicate that patients with indolent disease may be candidates for limited treatment with adjuvant endocrine therapy based on their very low risk of distant recurrences or death of breast cancer.

• Publication year

  2017

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2017-04-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-017-4262-0PMID 28451965PMCID 5487706
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Equivalence of MammaPrint array types in clinical trials and diagnostics

  2016influential reference
• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

  2016cited by this paper
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  2015cited by this paper
• Mammographic screening detects low-risk tumor biology breast cancers

  2014influential reference
• Long-term impact of the 70-gene signature on breast cancer outcome

  2014influential reference
• Performance characteristics of the MammaPrint® breast cancer diagnostic gene signature.

  2013cited by this paper
• A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

  2013influential reference
• Impact of mammographic screening on the detection of good and poor prognosis breast cancers

  2011influential reference
• Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

  2007influential reference
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006influential reference
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2006cited by this paper
• BMC Genomics BioMed Central Methodology article

  2005cited by this paper
• REporting recommendations for tumor MARKer prognostic studies (REMARK)

  2005cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• A gene-expression signature as a predictor of survival in breast cancer.

  2002cited by this paper

• Identification of Early-Stage Breast Cancer with a Minimal Risk of Recurrence by the Breast Cancer Index

  2025influential citation
• The Role of Molecular Profiling in De-Escalation of Toxic Therapy in Breast Cancer

  2025cites this paper
• Multi-transcriptomics predicts clinical outcome in systemically untreated breast cancer patients with extensive follow-up

  2025cites this paper
• Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1)

  2024cites this paper
• Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer

  2024cites this paper
• Ensemble‐based classification using microRNA expression identifies a breast cancer patient subgroup with an ultralow long‐term risk of metastases

  2024influential citation
• MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis

  2024cites this paper
• Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

  2024cites this paper
• Características clínico-patológicas y supervivencia de pacientes con cáncer de mama de riesgo muy bajo

  2022cites this paper
• Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial

  2022influential citation
• Clinicopathological characteristics and survival results of patients with ultralow risk breast cancer.

  2022cites this paper
• Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

  2022cites this paper
• Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy

  2022cites this paper
• Firmas génicas en el cáncer de mama

  2022cites this paper
• Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer.

  2022cites this paper
• The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy

  2022cites this paper
• Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer

  2021cites this paper
• Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer

  2021cites this paper
• MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients

  2021cites this paper
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer

  2020cites this paper
• Breast Cancer Assays of Genetic Expression in Tumor Tissue 09/01/19

  2020cites this paper
• Time intervals experienced between first symptom recognition and pathologic diagnosis of breast cancer in Addis Ababa, Ethiopia: a cross-sectional study

  2019cites this paper
• RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery

  2019cites this paper
• Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas

  2018cites this paper
• Role of dynamic contrast‐enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER‐positive, HER2‐negative, node‐negative invasive breast cancer

  2018cites this paper
• Title: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

  2017cites this paper
• Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

  2017cites this paper
• Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up

  2017cites this paper
• Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

  2017cites this paper
• FEP Medical Policy Manual

  2016cites this paper
• Technique

  1950cites this paper